In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

No benefit of thromboprophylaxis in medically ill patients MARINER trial

Commented by Oliver Schlager

Diseases of the Aorta, Peripheral Vascular Disease, Stroke

Rivaroxaban for thromboprophylaxis after hospitalization for medical illness

Spyropoulos AC et al.

The results of the multicenter randomized controlled MARINER trial (671 participating centers) were discussed at the ESC congress 2018 and published in the New England Journal of Medicine on 20th September 2018. The MARINER trial assessed the clinical benefit of a prolonged prophylactic anticoagulation with rivaroxaban versus placebo with respect to the prophylaxis of venous thromboembolism (VTE) in acutely medical ill patients.

The background of this study refers to the controversy on a prolonged thromboprophylaxis due to an ongoing risk of venous thromboembolism after hospital discharge. The inclusion criteria of MARINER were a hospitalization for at least 3 days (no longer than 10 days) for heart failure, respiratory insufficiency, stroke, an infectious or an inflammatory disease and an additional risk factor for VTE (defined as total modified International Medical Prevention Registry on Venous Thromboembolism risk score of ≥ 4, or a risk score of 2 or 3 plus a D-dimer > twice the upper limit). Included patients were randomized to receive either once-daily 10 mg rivaroxaban (or 7.5 mg in renal insufficiency) or placebo for 45 days, starting on the day of discharge (or the next day).

As main result, there was no benefit of prolonged prophylaxis with once-daily 10 mg rivaroxaban regarding a reduction of the primary efficacy endpoint, which was

the composite of symptomatic VTE or VTE-related death. Among secondary endpoints, the risk of the occurrence of symptomatic VTE (analyzed separately) and the composite of symptomatic VTE and death from any cause were lowered by the prophylactic dose of rivaroxaban. However, regarding safety, nonmajor clinically relevant bleedings, other bleedings as well as transfusions of ≥ 2 units of packed red blood cells occurred more frequent in the rivaroxaban group. Referring to these observations, the number needed to treat to prevent one symptomatic VTE was 430 and the number needed to treat to cause one bleeding was 856.

In conclusion, the MARINER trial showed no benefit of a prolonged rivaroxaban administration in medically ill patients as VTE prophylaxis. Despite this negative trial result, MARINER provides clearer insights in the discussion on prolonged VTE prophylaxis with non-vitamin K antagonist oral anticoagulants (NOAC) in medically ill patients. This is an important contribution, since previous trials, such as MAGELLAN and ADOPT, primarily compared prophylactic NOAC regimens with shorter durations of prophylactic low-molecular weight heparins instead of comparing with placebo.



Spyropoulos AC, Ageno W, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard GA, Steg PG, Weitz JI, Suh E, Spiro TE, Barnathan ES, Raskob GE; MARINER Investigators. Rivaroxaban for thromboprophylaxis after hospitalization for medical illness. N Engl J Med 2018;379(12):1118-27.

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.

Contact us

ESC Working Group on Aorta & Peripheral Vascular Diseases

European Society of Cardiology

European Heart House
Les Templiers
2035 Route des Colles
CS 80179 Biot

06903, Sophia Antipolis, FR

Tel: +